Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15800267 | 0.85 | PTGS2 (0.45) | PTGS2ENPP2EPHX2NR1H4RORC | |
| SCHEMBL23343670 | 0.83 | CA2 (0.61) | CA12CA1CA2CA9 | |
| SCHEMBL10202790 | 0.82 | PTGS2 (0.43) | PTGS2ENPP2EPHX2NR1H4GPR119 | |
| SCHEMBL648537 | 0.81 | AGXT (0.39) | — | |
| SCHEMBL15677618 | 0.79 | PTGS2 (0.43) | PTGS2ENPP2RORCCA12CA1 | |
| SCHEMBL5522736 | 0.78 | PTGS2 (0.70) | PTGS2ENPP2CA12CA1CA2 | |
| SCHEMBL24507590 | 0.77 | ENPP2 (0.52) | PTGS2ENPP2CA12CA1CA2 | |
| SCHEMBL3850384 | 0.76 | PTGS2 (0.50) | PTGS2ENPP2CA12CA1CA2 | |
| SCHEMBL6480783 | 0.76 | CA12 (0.68) | PTGS2ENPP2CA12CA1CA2 | |
| SCHEMBL26398329 | 0.75 | PTGS2 (0.43) | PTGS2ENPP2EPHX2NR1H4GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9119822-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | OMEROS CORPORATION (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179717-A1 | Use of PDE7 Inhibitors for the Treatment of Movement Disorders | PARK7, PDE7B, PDE7A | PTGS2 2105/4885ENPP2 208/4885EPHX2 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.